foxo4-dri senolytic peptide human trials Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging FOXO4-DRI: Human Trial Status, Cancer
FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data FOXO4 DRI Averix Labs Development of a novel senolytic by precise disruption of FOXO4 p53 complex eBioMedicine Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv Frontiers FOXO4 DRI regulates endothelial cell senescence via the P53 signaling pathway
Pay in 4 interest-free payments of $5.83 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5




